Longevity loss among cured tuberculosis patients and the potential value of prevention
about
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosisAdvancing host-directed therapy for tuberculosis.M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection.Risk of Sarcopenia and Osteoporosis in Male Tuberculosis Survivors: Korea National Health and Nutrition Examination Survey.
P2860
Longevity loss among cured tuberculosis patients and the potential value of prevention
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Longevity loss among cured tuberculosis patients and the potential value of prevention
@ast
Longevity loss among cured tuberculosis patients and the potential value of prevention
@en
Longevity loss among cured tuberculosis patients and the potential value of prevention
@nl
type
label
Longevity loss among cured tuberculosis patients and the potential value of prevention
@ast
Longevity loss among cured tuberculosis patients and the potential value of prevention
@en
Longevity loss among cured tuberculosis patients and the potential value of prevention
@nl
prefLabel
Longevity loss among cured tuberculosis patients and the potential value of prevention
@ast
Longevity loss among cured tuberculosis patients and the potential value of prevention
@en
Longevity loss among cured tuberculosis patients and the potential value of prevention
@nl
P2093
P2860
P3181
P356
P1476
Longevity loss among cured tuberculosis patients and the potential value of prevention
@en
P2093
P2860
P304
P3181
P356
10.5588/IJTLD.14.0242
P407
P577
2014-11-01T00:00:00Z